Syncona Limited Change in Investment Manager

 
TIDMSYNC 
 
Syncona Limited 
 
                         Change in Investment Manager 
 
12 December 2017 
 
Syncona Ltd, a leading healthcare company focused on investing in and building 
global leaders in life science, today announces that it has appointed its 
subsidiary Syncona Investment Management Limited (SIML) as its investment 
manager and AIFM for the purposes of the AIFM Directive.  This appointment is 
with effect from 12 December 2017 and is as envisaged at the time of the change 
of the Company's investment policy and acquisition of the life science 
portfolio of Syncona Partners LLP approved by the Company's shareholders in 
December 2016. 
 
BACIT (UK) Limited, the former investment manager and AIFM of the Company, 
continues to be engaged by SIML as a sub-delegate to manage the funds 
portfolio, on the same terms. 
 
[ENDS] 
 
Enquiries 
 
Syncona Ltd 
Siobhan Weaver 
Tel: [phone] 
 
 
 
Notes to Editors 
 
About Syncona: 
 
Syncona is a leading FTSE250 healthcare company focused on investing in and 
building global leaders in life science. Our vision is to deliver 
transformational treatments to patients in truly innovative areas of healthcare 
while generating superior returns for shareholders. Our current investment 
portfolio consists of seven high quality companies in life science and a 
leading range of fund investments. 
 
We seek to partner with the best, brightest and most ambitious minds in science 
to build globally competitive businesses. We are established leaders in gene 
therapy, cell therapy and advanced diagnostics, and focus on delivering 
dramatic efficacy for patients in areas of high unmet need. 
 
Our market leading funds portfolio seeks to generate superior returns by 
investing in long only and alternative investment funds. This represents a 
productively deployed evergreen funding base which enables us to take a long 
term approach to investing in life sciences as we target the best new 
opportunities and support our existing portfolio companies to grow and succeed. 
 
Syncona is aligned with two of the premium charitable funders in UK science, 
the Wellcome Trust, original founder of Syncona, and Cancer Research UK, both 
of which are significant shareholders in our business.  We make a donation of 
0.3% of Net Asset Value to a range of charities each year. 
 
 
 
END 
 

(END) Dow Jones Newswires

December 12, 2017 10:24 ET (15:24 GMT)